linjc16/ctgov huggingface dataset:
A Clinical Study of BRCA and DNA Damage Repair Genes in Blood Samples of Chinese Pancreatic Cancer Patients

Study Overview
=================
Brief Summary
-----------------
This study aims to know the status of BRCA and DDR genes in PDAC patients in China. Peripheral venous blood samples of the patients will be collected for next-generation sequencing of BRCA and DNA damage repair related genes. At the same time, it is necessary to record clinical information such as age, gender, tumor pathological type, tumor stage and grade, whether surgery is performed, the size of postoperative residual lesions, and treatment methods. Prognostic indicators include the association of factors such as PFS, ORR, and DCR are also recorded.

Official Title
-----------------
A Prospective Multicenter Clinical Study of BRCA and DNA Damage Repair Genes in Blood Samples of Chinese Pancreatic Cancer Patients

Conditions
-----------------
Pancreatic Cancer

Intervention / Treatment
-----------------
* Other: Observation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients diagnosed with pancreatic cancer PS score ≤ 2 no severe heart, cerebrovascular disease, severe coagulation dysfunction or severe mental disorder Exclusion Criteria: PS score > 2 with severe heart, cerebrovascular disease, severe coagulation dysfunction or severe mental disorder

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Observation|This study is an observe research|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| OS | Overall survival | 2years |
Attempts to Stop/Reduce Marijuana Among Dependent Users

Study Overview
=================
Brief Summary
-----------------
The purpose of the study is to determine why and how marijuana users stop or reduce their marijuana use.

Detailed Description
-----------------
The major aim of this study is to provide a better understanding of attempts to stop or reduce marijuana use that can be used to develop better behavioral treatments for marijuana dependence. The application will focus on adult daily marijuana users who try to stop or reduce their marijuana use in a real-world setting. Although prospective, natural history studies describing attempts to stop or reduce alcohol, heroin and tobacco use have proved useful, we know of no such study among adult marijuana users. Two pilot studies will develop measures and assess compliance with our procedures. The main study will recruit up to 400 adult marijuana smokers with the goal of a sample size of 200 participants with adequate compliance. Participants will call an Interactive Voice Recording (IVR) system daily for 3 months to report marijuana use, quit/reduction attempts, and events that might increase or decrease the probability of initiating a quit/reduction attempt or the success of an attempt. Follow-up at 6 months will track recent marijuana and other drug use. Knowing what motivates marijuana users to try to stop or reduce, and knowing which strategies for stopping marijuana use are successful, can help develop treatments for marijuana dependence. For example, if stopping tobacco when trying to stop marijuana decreases the chance of stopping marijuana, then smoking cessation should be done after stopping marijuana. Or if reducing marijuana often leads to cessation, then convincing those not interested in quitting marijuana to first try reducing may be helpful.

Official Title
-----------------
Attempts to Stop/Reduce Marijuana Among Dependent Users

Conditions
-----------------
Marijuana Abuse, Marijuana Dependence

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: daily marijuana smokers for at least 1 year Exclusion Criteria: pregnant women

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| initiation of a quit or reduction attempt |  | during 3 months of monitoring | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| duration of a quit attempt |  | during the 3 months of monitoring | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
marijuana, marijuana abuse, marijuana dependence, cannabis, substance-related disorder, abstinence
Safety, Tolerability and Pharmacokinetic Study of MT-3995 at a Low Dose in Subjects With Diabetic Nephropathy

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate safety, tolerability and pharmacokinetics of MT-3995 in Subjects with Diabetic Nephropathy.

Official Title
-----------------
A Phase II, Randomised, Double-blind, Placebo-controlled Study of MT-3995 (Low Dose) in Subjects With Diabetic Nephropathy

Conditions
-----------------
Diabetic Nephropathy

Intervention / Treatment
-----------------
* Drug: MT-3995
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Subjects with Type 2 diabetes mellitus and diabetic nephropathy, who have been treated with a stable dose of angiotensin converting enzyme-inhibitor (ACE-I) or angiotensin II receptor blocker (ARB) Glycosylated haemoglobin (HbA1c) ≤10.5% Subject with albuminuria Exclusion Criteria: Subjects with type 1 diabetes mellitus, diabetes mellitus resulting from pancreatic disorder, secondary diabetes mellitus (Cushing's syndrome, steroidogenic diabetes). Serum potassium level <3.5 or >5.0 mmol/L Subjects who had acute kidney injury within 3 months prior to baseline or have undergone hemodialysis at any time prior to randomisation Subjects with clinically significant hypotension

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: MT-3995<br> | Drug: MT-3995<br> <br> |
| Placebo Comparator: Placebo<br> | Drug: Placebo<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Frequency and nature of treatment-emergent adverse events and serious adverse events. |  | 20 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Plasma concentrations of MT-3995 |  | 20 weeks | 
| Plasma concentrations of major metabolite of MT-3995 |  | 20 weeks | 
| Change from baseline in Urine albumin-to-creatinine ratio (UACR) |  | 20 weeks | 
| Change from baseline in blood pressure |  | 20 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Diabetic Nephropathy
Study on the Protective Effect of RIPC in Patients Undergoing Cardiac Surgery.

Study Overview
=================
Brief Summary
-----------------
To observe the effect of RIPC on the function of vital organs after cardiac surgery, and to explore its possible mechanism.

Official Title
-----------------
Study on the Protective Effect of RIPC in Patients Undergoing Cardiac Surgery.

Conditions
-----------------
Cardiac Surgery

Intervention / Treatment
-----------------
* Device: RIPC


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients with aortic valve, mitral valve, tricuspid valve, ascending aortic disease and coronary atherosclerosis who were admitted to hospital for elective valve repair, replacement, artificial vascular replacement or coronary artery bypass grafting. age 18-80 years old. No restriction on gender. ASA grade II III. NYHAII III level. the patient or his family member has signed the informed consent form for the clinical trial Exclusion Criteria: those who are disabled in the selected test. less than 5 years of education. The preoperative left ventricular ejection fraction ((LVEF)) was less than 40%. Myocardial infarction occurred in nearly one month. malignant tumor, hematological disease, severe liver and kidney dysfunction, recent severe infection, etc. History of nervous system, immune system and mental illness. recent operation history of heart, brain, lung, liver, kidney and other important organs

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: RIPC<br> | Device: RIPC<br>* The tourniquet attached to the upper limb was inflated and blocked for 5 minutes, then deflated for 5 minutes to restore blood flow and induce ischemic preconditioning.<br>|
| No Intervention: Control<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The incidence of acute renal injury after operation | According to the (KDIGO) guidelines for improving the prognosis of renal disease | within 7 days after operation | 
| The incidence of postoperative delirium | CAM score greater than 22 | within 7 days after operation |
The Clinical Application of Tauroursodeoxycholic Acid in Patients With Liver Fibrosis.

Study Overview
=================
Brief Summary
-----------------
This study is a prospective study. We signed an informed consent form with patients with liver fibrosis and took tauroursodeoxycholic acid orally for half a year. After half a year, liver biopsy was performed using histopathology, immunohistochemistry, and polymerase chain reaction, Western blotting method was used to determine the expression level of fibrosis-related markers to verify the effect of taurodeoxycholic acid on patients with liver fibrosis.

Detailed Description
-----------------
Tauroursodeoxycholic acid is an effective component of bear bile, which has obvious curative effects in the treatment of gallstones and liver diseases. In recent years, the research field of tauroursodeoxycholic acid has been very active, and its chemical synthesis has also attracted much attention. The usage is swallowing with water before going to bed at night. It must be taken regularly, one capsule at a time (250mg), once a day. After 6 months of continuous use, liver biopsy was performed after 6 months. Telling the patient to swallow with water before going to bed at night. It must be taken regularly, one capsule at a time (250mg), once a day. After 6 months of continuous use, liver B-ultrasound biopsy was performed to observe the effect.

Official Title
-----------------
The Clinical Application of Tauroursodeoxycholic Acid in Patients With Liver Fibrosis.

Conditions
-----------------
Liver Cirrhosis

Intervention / Treatment
-----------------
* Drug: Tauroursodeoxycholic acid
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Clinical diagnosis of liver cirrhosis and liver fibrosis in patients requiring medical treatment. Exclusion Criteria: Patients with end-stage cirrhosis, liver failure, etc. who need liver transplantation.

Ages Eligible for Study
-----------------
Minimum Age: 30 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: patient+TUDCA<br> | Drug: Tauroursodeoxycholic acid<br>* Oral TUDCA, once a day, one tablet (250mg) at a time for 6 months<br>|
| Placebo Comparator: patient+placebo<br> | Drug: Placebo<br>* Oral placebo, once a day, one tablet at a time for 6 months<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Liver biopsy | Synthesis of liver extracellular matrix（Synthesis, degradation） | up to 24 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Liver ultrasound | Liver parenchymal echo（Normal, dense, thickened） | up to 24 weeks |
Prediction of Weight Gain by Children and Adolescents

Study Overview
=================
Brief Summary
-----------------
The 'Meir children's sport and health center' runs a multi-disciplinary intervention program for the treatment of overweight and obese children and adolescents. The program includes physical activity, dietary guidelines, medical supervision and behavioral treatment. The participants are routinely weighed once a week, at the same day and time, in order to supervise their progress. According to our experience, the child can predict his weight change, based on his behavior in the previous week. To our knowledge the overweight/obese child's ability to predict his weekly weight change, while participating in a multi-disciplinary intervention program, has never been tested.

Detailed Description
-----------------
The aim of this study is to examine whether a child participating in a multi-disciplinary intervention program for treatment of the overweight and obese in Meir medical center, can predict his weight change during intervention before the actual weighing. This study will include 1000 weight measurements of children and adolescents, boys and girls, ages 5-18 years. A patient might be measured several times. The data will be collected during 6 mounts. in this period the program participants will be asked, discretely, before being weighed if, in there opinion, they had lost or gained weight in the past week, and how mach and why.

Official Title
-----------------
Prediction of Weight Gain by Children and Adolescents That Participate in a Multi-disciplinary Intervention Program for Treatment of Overweight and Obese

Conditions
-----------------
Overweight, Obesity

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Overweight and obese children and adolescence Boys and girls Ages 5-18 That taking pat in a multi-disciplinary intervention program for treatment of the overweight and obese in Meir medical center

Ages Eligible for Study
-----------------
Minimum Age: 5 Years
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| weight measurements<br>This study include 1000 weight measurements of children and adolescence, boys and girls, ages 5-18, that taking pat in a multi-disciplinary intervention program for treatment of the overweight and obese in Meir medical center. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Participants will be able to predict their weight change |  | 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
overweight, obese, children, weighing, weight
Using Motivational Interviewing To Reduce Parental Risk-Related Behaviors For Early Childhood Caries

Study Overview
=================
Brief Summary
-----------------
The study's aim was to investigate if a motivational interviewing intervention (MI) improved oral self-care behaviors of AIAN caregivers of infants and determine if the MI intervention promoted positive changes in caregivers' ECC risk-related behaviors.

Official Title
-----------------
Using Motivational Interviewing To Reduce Parental Risk-Related Behaviors For Early Childhood Caries

Conditions
-----------------
Caries,Dental, Caries

Intervention / Treatment
-----------------
* Behavioral: Motivational Interviewing


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: - healthy mothers/caregivers of infants Exclusion Criteria: Subjects with recent antibiotic use (within 3 months) Subjects on any medication that is immunosuppressive Subjects who self-report they have xerostomia due to medication use

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Treatment Group<br>The treatment group received motivational interviewing. | Behavioral: Motivational Interviewing<br>* Participants/caregivers will receive several telephone-based and in-person motivational interviewing sessions along with specific oral health recommendations.<br>|
| No Intervention: Control Group<br>The control group received standard information only. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in Concentration of Lactobacilli | Oral concentration of Lactobacilli will be measured using a Caries Risk Test (CRT). Outcome will be reported in colony-forming units per milliliter (CFU/mL). | Baseline, 8 months | 
| Change in Concentration of Mutans Streptococcus | Oral concentration of Mutans streptococcus will be measured using a Caries Risk Test (CRT). Outcome will be reported in colony-forming units per milliliter (CFU/mL). | Baseline, 8 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Early Childhood Caries, Motivational Interviewing
Immediate Effects of Dry Needling and Tens in Chronic Neck Pain

Study Overview
=================
Brief Summary
-----------------
The aim of this study is to determinate the effects of percutaneous electrical nerve stimulation in the short-term for pain in patients with myofascial chronic neck pain.

Official Title
-----------------
IMMEDIATE EFFECTS OF DRY NEEDLING VERSUS DRY NEEDLING AND TENS ON PAIN IN PATIENTS WITH CHRONIC MIOFASCIAL NECK PAIN

Conditions
-----------------
Myofascial Neck Pain

Intervention / Treatment
-----------------
* Other: Dry Needling
* Other: TENS and dry needling


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Neck pain for more than six months of evolution. Active Myofascial Trigger Point number 2 on Trapezius muscle. Score of more than 2 points in a Visual Analog Scale. Exclusion Criteria: Neck pain specific. Radiculopathies. Whiplash. Dizziness and migraines Cervical surgical intervention Previous treatment of Dry Needling

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 48 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Dry needling<br>Dry needling treatment on the trigger point number 2 of the trapezius muscle. | Other: Dry Needling<br>* Needling with acupuncture needle in a myofascial trigger point.<br>|
| Active Comparator: TENS and dry needling<br>Application of TENS current after dry needling treatment. | Other: TENS and dry needling<br>* Application of TENS current after dry needling technique<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Neck Pain | Visual analog scale. A 100mm VAS, ranging from 0mm (no pain) to 100mm (worst imaginable pain). | 4 days | 
| Post-needling pain | Visual analog scale. A 100mm VAS, ranging from 0mm (no pain) to 100mm (worst imaginable pain). | 4 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pressure Pain threshold | Pressure needed to evoke pain recognized by patient. Measured using an algometer in Kg/cm2 | 4 days | 
| Range of Motion | The subjects sat in a chair and a CROM goniometer was placed over the head. They were asked to perform active neck movements to the fullest extent of their mobility. Each movement was recorded three times and the average value was calculated. | 4 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Neck pain, Myofascial pain syndrome, Soreness